Cite
Very high-dose methotrexate (33.6 g/m2) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P.
MLA
Nathan, Paul C., et al. “Very High-Dose Methotrexate (33.6 g/M2) as Central Nervous System Preventive Therapy for Childhood Acute Lymphoblastic Leukemia: Results of National Cancer Institute/Children’s Cancer Group Trials CCG-191P, CCG-134P and CCG-144P.” Leukemia & Lymphoma, vol. 47, no. 12, Dec. 2006, pp. 2488–504. EBSCOhost, https://doi.org/10.1080/10428190600942769.
APA
Nathan, P. C., Whitcomb, T., Wolters, P. L., Steinberg, S. M., Balis, F. M., Brouwers, P., Hunsberger, S., Feusner, J., Sather, H., Miser, J., Odom, L. F., Poplack, D., Reaman, G., & Bleyer, W. A. (2006). Very high-dose methotrexate (33.6 g/m2) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children’s Cancer Group trials CCG-191P, CCG-134P and CCG-144P. Leukemia & Lymphoma, 47(12), 2488–2504. https://doi.org/10.1080/10428190600942769
Chicago
Nathan, Paul C., Trish Whitcomb, Pamela L. Wolters, Seth M. Steinberg, Frank M. Balis, Pim Brouwers, Sally Hunsberger, et al. 2006. “Very High-Dose Methotrexate (33.6 g/M2) as Central Nervous System Preventive Therapy for Childhood Acute Lymphoblastic Leukemia: Results of National Cancer Institute/Children’s Cancer Group Trials CCG-191P, CCG-134P and CCG-144P.” Leukemia & Lymphoma 47 (12): 2488–2504. doi:10.1080/10428190600942769.